头孢他啶-阿维巴坦治疗耐碳青霉烯类肠杆菌科细菌感染患者结局的多中心研究
Multicenter Study of Outcomes with Ceftazidime-Avibactam in Patients with Carbapenem-Resistant Enterobacteriaceae Infections.
作者信息
King Madeline, Heil Emily, Kuriakose Safia, Bias Tiffany, Huang Vanthida, El-Beyrouty Claudine, McCoy Dorothy, Hiles Jon, Richards Lynette, Gardner Julianne, Harrington Nicole, Biason Kenneth, Gallagher Jason C
机构信息
Philadelphia College of Pharmacy, Philadelphia, Pennsylvania, USA.
University of Maryland School of Pharmacy, Baltimore, Maryland, USA.
出版信息
Antimicrob Agents Chemother. 2017 Jun 27;61(7). doi: 10.1128/AAC.00449-17. Print 2017 Jul.
Abstract
Ceftazidime-avibactam is a novel cephalosporin-beta-lactamase inhibitor combination that is active against many carbapenem-resistant (CRE). We describe a retrospective chart review for 60 patients who received ceftazidime-avibactam for a CRE infection. In-hospital mortality was 32%, 53% of patients had microbiological cure, and 65% had clinical success. In this severely ill population with CRE infections, ceftazidime-avibactam was an appropriate option.
摘要
头孢他啶-阿维巴坦是一种新型的头孢菌素-β-内酰胺酶抑制剂组合，对多种耐碳青霉烯类肠杆菌科细菌（CRE）具有活性。我们对60例接受头孢他啶-阿维巴坦治疗CRE感染的患者进行了回顾性病历审查。住院死亡率为32%，53%的患者实现了微生物学治愈，65%的患者取得了临床成功。在这群患有CRE感染的重症患者中，头孢他啶-阿维巴坦是一个合适的选择。
相似文献
1
Multicenter Study of Outcomes with Ceftazidime-Avibactam in Patients with Carbapenem-Resistant Enterobacteriaceae Infections.头孢他啶-阿维巴坦治疗耐碳青霉烯类肠杆菌科细菌感染患者结局的多中心研究
Antimicrob Agents Chemother. 2017 Jun 27;61(7). doi: 10.1128/AAC.00449-17. Print 2017 Jul.
2
Clinical experience with ceftazidime/avibactam for treatment of antibiotic-resistant organisms other than Klebsiella pneumoniae.治疗除肺炎克雷伯菌以外的耐药菌的头孢他啶/阿维巴坦的临床经验。
Int J Antimicrob Agents. 2018 Apr;51(4):629-635. doi: 10.1016/j.ijantimicag.2018.01.016. Epub 2018 Feb 2.
3
Treating complicated carbapenem-resistant enterobacteriaceae infections with ceftazidime/avibactam: a retrospective study with molecular strain characterisation.使用头孢他啶/阿维巴坦治疗复杂碳青霉烯类耐药肠杆菌科感染：一项结合分子菌株特征的回顾性研究。
Int J Antimicrob Agents. 2017 Jun;49(6):770-773. doi: 10.1016/j.ijantimicag.2017.01.018. Epub 2017 Apr 4.
4
Clinical characteristics and prognosis of infections caused by OXA-48 carbapenemase-producing Enterobacteriaceae in patients treated with ceftazidime-avibactam.产 OXA-48 碳青霉烯酶肠杆菌科细菌感染患者应用头孢他啶-阿维巴坦治疗的临床特征和预后
Int J Antimicrob Agents. 2019 Apr;53(4):520-524. doi: 10.1016/j.ijantimicag.2018.11.015. Epub 2018 Nov 22.
5
Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae.多黏菌素与头孢他啶-阿维巴坦治疗碳青霉烯类耐药肠杆菌科细菌感染。
Clin Infect Dis. 2018 Jan 6;66(2):163-171. doi: 10.1093/cid/cix783.
6
Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant Infections.美罗培南-维巴坦与头孢他啶-阿维巴坦治疗碳青霉烯类耐药感染。
Antimicrob Agents Chemother. 2020 Apr 21;64(5). doi: 10.1128/AAC.02313-19.
7
Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections.耐碳青霉烯类肠杆菌科细菌感染患者的临床结局、药物毒性及头孢他啶-阿维巴坦耐药性的出现
Clin Infect Dis. 2016 Dec 15;63(12):1615-1618. doi: 10.1093/cid/ciw636. Epub 2016 Sep 13.
8
Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms.头孢他啶-阿维巴坦：一种用于治疗耐药革兰氏阴性菌的新型头孢菌素/β-内酰胺酶抑制剂组合
Clin Ther. 2016 Mar;38(3):431-44. doi: 10.1016/j.clinthera.2016.01.018. Epub 2016 Mar 2.
9
Effectiveness of ceftazidime/avibactam as salvage therapy for treatment of infections due to OXA-48 carbapenemase-producing Enterobacteriaceae.头孢他啶/阿维巴坦作为治疗产 OXA-48 碳青霉烯酶肠杆菌科感染的补救治疗的疗效。
J Antimicrob Chemother. 2018 Nov 1;73(11):3170-3175. doi: 10.1093/jac/dky295.
10
Efficacy of ceftazidime-avibactam in the treatment of infections due to Carbapenem-resistant Enterobacteriaceae.头孢他啶-阿维巴坦治疗碳青霉烯类耐药肠杆菌科细菌感染的疗效。
BMC Infect Dis. 2019 Sep 4;19(1):772. doi: 10.1186/s12879-019-4409-1.
引用本文的文献
1
Ceftazidime-Avibactam in Critically Ill Patients: A Multicenter Observational Study.头孢他啶-阿维巴坦用于重症患者：一项多中心观察性研究。
Antibiotics (Basel). 2025 Aug 5;14(8):797. doi: 10.3390/antibiotics14080797.
2
Clinical efficacy, safety and pharmacokinetics of novel β-lactam/β-lactamase inhibitor combinations: a systematic review.新型β-内酰胺/β-内酰胺酶抑制剂联合用药的临床疗效、安全性及药代动力学：一项系统评价
JAC Antimicrob Resist. 2025 Jun 19;7(3):dlaf096. doi: 10.1093/jacamr/dlaf096. eCollection 2025 Jun.
3
The efficacy of polymyxin B in treating stroke-associated pneumonia with carbapenem-resistant Gram-negative bacteria infections: a multicenter real-world study using propensity score matching.多粘菌素B治疗耐碳青霉烯类革兰阴性菌感染的卒中相关性肺炎的疗效：一项使用倾向评分匹配的多中心真实世界研究
Front Pharmacol. 2025 Mar 20;16:1413563. doi: 10.3389/fphar.2025.1413563. eCollection 2025.
4
Are New β-Lactam/β-Lactamase Inhibitor Combinations Promising Against Carbapenem-Resistant Isolates?新型β-内酰胺/β-内酰胺酶抑制剂组合对耐碳青霉烯类分离株是否有前景？
Pathogens. 2025 Feb 24;14(3):220. doi: 10.3390/pathogens14030220.
5
Mortality-related risk factors of carbapenem-resistant Enterobacteriaceae infection with focus on antimicrobial regimens optimization: a real-world retrospective study in China.耐碳青霉烯类肠杆菌科细菌感染的死亡相关危险因素及抗菌方案优化：一项中国的真实世界回顾性研究
BMC Infect Dis. 2025 Jan 23;25(1):110. doi: 10.1186/s12879-025-10454-z.
6
Efficiency of combination therapy versus monotherapy for the treatment of infections due to carbapenem-resistant Gram-negative bacteria: a systematic review and meta-analysis.联合治疗与单一疗法治疗耐碳青霉烯类革兰氏阴性菌感染的疗效：一项系统评价和荟萃分析。
Syst Rev. 2024 Dec 19;13(1):309. doi: 10.1186/s13643-024-02695-x.
7
A systematic review of efficacy and safety of newer drugs approved from 2016 to 2023 for the treatment of complicated urinary tract infections.2016 年至 2023 年批准用于治疗复杂性尿路感染的新药疗效和安全性的系统评价。
Ann Med. 2024 Dec;56(1):2403724. doi: 10.1080/07853890.2024.2403724. Epub 2024 Nov 12.
8
Ceftazidime-Avibactam as a Salvage Treatment for Severely Infected Immunosuppressed Children.头孢他啶-阿维巴坦作为挽救治疗严重感染免疫抑制儿童的药物。
Drug Des Devel Ther. 2024 Jul 30;18:3399-3413. doi: 10.2147/DDDT.S467967. eCollection 2024.
9
Management of intra-abdominal infections: recommendations by the Italian council for the optimization of antimicrobial use.腹腔内感染的管理：意大利抗菌药物优化使用理事会的建议。
World J Emerg Surg. 2024 Jun 8;19(1):23. doi: 10.1186/s13017-024-00551-w.
10
Ceftazidime-Avibactam in the Treatment of Patients with Bacteremia or Nosocomial Pneumonia: A Systematic Review and Meta-analysis.头孢他啶-阿维巴坦治疗菌血症或医院获得性肺炎患者：一项系统评价和荟萃分析
Infect Dis Ther. 2024 Jul;13(7):1639-1664. doi: 10.1007/s40121-024-00999-y. Epub 2024 May 31.
本文引用的文献
1
Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections.耐碳青霉烯类肠杆菌科细菌感染患者的临床结局、药物毒性及头孢他啶-阿维巴坦耐药性的出现
Clin Infect Dis. 2016 Dec 15;63(12):1615-1618. doi: 10.1093/cid/ciw636. Epub 2016 Sep 13.
2
Sepsis: pathophysiology and clinical management.脓毒症：病理生理学与临床管理。
BMJ. 2016 May 23;353:i1585. doi: 10.1136/bmj.i1585.
3
Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program.头孢他啶-阿维巴坦联合甲硝唑与美罗培南治疗复杂性腹腔内感染的疗效和安全性：一项随机、对照、双盲、3期研究的结果
Clin Infect Dis. 2016 Jun 1;62(11):1380-1389. doi: 10.1093/cid/ciw133. Epub 2016 Mar 8.
4
Deaths attributable to carbapenem-resistant Enterobacteriaceae infections.由耐碳青霉烯类肠杆菌科细菌感染导致的死亡病例。
Emerg Infect Dis. 2014 Jul;20(7):1170-5. doi: 10.3201/eid2007.121004.
5
Ceftazidime-avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections.头孢他啶-阿维巴坦：基于证据对其药理学及治疗革兰氏阴性菌感染潜在用途的综述
Core Evid. 2014 Jan 24;9:13-25. doi: 10.2147/CE.S40698. eCollection 2014.
6
Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial.头孢他啶/阿维巴坦联合甲硝唑与美罗培南治疗住院成人复杂性腹腔内感染的疗效和安全性比较：一项随机、双盲、II 期临床试验结果。
J Antimicrob Chemother. 2013 May;68(5):1183-92. doi: 10.1093/jac/dks523. Epub 2013 Feb 7.
7
Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes.碳青霉烯类耐药肠杆菌科细菌：治疗与结局的综述。
Diagn Microbiol Infect Dis. 2013 Feb;75(2):115-20. doi: 10.1016/j.diagmicrobio.2012.11.009. Epub 2013 Jan 3.
8
Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens.产 KPC 肺炎克雷伯菌血症的治疗转归：联合抗菌方案的优势。
Antimicrob Agents Chemother. 2012 Apr;56(4):2108-13. doi: 10.1128/AAC.06268-11. Epub 2012 Jan 17.
9
International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial Infections.肺炎克雷伯菌菌血症的国际前瞻性研究：产超广谱β-内酰胺酶在医院感染中的影响
Ann Intern Med. 2004 Jan 6;140(1):26-32. doi: 10.7326/0003-4819-140-1-200401060-00008.
10
A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.纵向研究中预后合并症分类的一种新方法：开发与验证
J Chronic Dis. 1987;40(5):373-83. doi: 10.1016/0021-9681(87)90171-8.
Zotero 插件